EDINBURGH, Scotland, March 1,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that Chief Executive Officer, Bryan
Kobel was again featured on a live interview on "The Big Biz
Show," an Emmy Award-winning nationally syndicated TV and radio
show.
Bryan Kobel, CEO stated, "It was
great to reconnect with 'Sully' and his crew in order to provide an
update on all the exciting developments that are going on at TC
BioPharm."
The interview will be aired on cable TV and streaming services,
including Roku, as well as on radio via The Biz Talk Radio Network,
Armed Forces Radio, and iHeart Media in 175 countries.
Podcasts of the show will be available on iHeart Radio, Apple
Podcasts, Speaker.com, and TuneIn, as well as to subscribers of
biztv.com or ytaclub.com.
About the Big Biz Show
Widely regarded as "Business with a Bite," the Big Biz Show is
an Emmy Award-winning nationally syndicated radio and TV program.
The fast-talking, hard-hitting show is hosted by Bob "Sully"
Sullivan, who is also a weekly contributor on the FOX Business
Network. For more information, go
to bigbizshow.com.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach to effectively identify, target and
eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for
OmnImmune® in treatment of acute myeloid leukemia using the
Company's proprietary allogenic CryoTC technology to provide frozen
product to clinics worldwide. TC BioPharm also maintains a robust
pipeline for future indications in solid tumors as well as a
significant IP/patent portfolio and owns its manufacturing facility
to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking
nature relating to future events. These forward-looking statements
are subject to the inherent uncertainties in predicting future
results and conditions. These statements reflect our current
beliefs, and a number of important factors could cause actual
results to differ materially from those expressed in this press
release. We undertake no obligation to revise or update any
forward-looking statements, whether as a result of new information,
future events or otherwise. The reference to the website of TC
BioPharm has been provided as a convenience, and the information
contained on such website is not incorporated by reference into
this press release.
Click here for Interview:
https://www.youtube.com/watch?v=DQ8pdK6iv-s
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bryan-kobel-ceo-of-tcbp-appears-on-nationally-syndicated-the-big-biz-show-302077143.html
SOURCE TC BioPharm